133261-33-3

Usage

Uses

Used in Pharmaceutical Industry:
TRANS-4-(TRIFLUOROMETHYL)CYCLOHEXANECARBOXYLIC ACID is used as a key intermediate in the synthesis of antiviral agents for the treatment of various viral infections. Its unique structure allows it to interact with viral enzymes or proteins, thereby inhibiting viral replication and reducing the severity of the infection.
Used in Antiviral Drug Development:
TRANS-4-(TRIFLUOROMETHYL)CYCLOHEXANECARBOXYLIC ACID is utilized in the development of antiviral drugs to combat a wide range of viral diseases. Its incorporation into drug molecules can enhance their efficacy, selectivity, and resistance to viral mutations, making it a promising candidate for the creation of novel antiviral therapies.

InChI:InChI=1/C8H11F3O2/c9-8(10,11)6-3-1-5(2-4-6)7(12)13/h5-6H,1-4H2,(H,12,13)/t5-,6-

Upstream product

• 455-24-3 4-trifluoromethylbenzoic acid 

Downstream Products

• 1204296-05-8 methyl 4-trifluoromethylcyclohexanecarboxylate 
• 1202575-61-8 (3S)-3-ethoxy-3-(4-{[trans-4-(trifluoromethyl)cyclohexyl]methoxy}phenyl)propionic acid 
• 1202577-61-4 ((1r,4r)-4-(trifluoromethyl)cyclohexyl)methanol 
• 1202577-62-5 Methyl (3S)-3-ethoxy-3-(4-{[trans-4-(trifluoromethyl)cyclohexyl]methoxy}phenyl)propionate 
• 133261-34-4 trans-4-(trifluoromethyl)cyclohexane-1-carbaldehyde 
• 1621225-45-3 6-(((R)-1-cyclobutylethyl)amino)-7-((trans-4-(trifluoromethyl)cyclohexyl)methyl)-7H-purine-2-carbonitrile 
• 1621225-44-2 2-chloro-N-((R)-1-cyclobutylethyl)-7-((trans-4-(trifluoromethyl)cyclohexyl)methyl)-7H-purin-6-amine 
• 1621225-42-0 2,6-dichloro-7-((trans-4-(trifluoromethyl)cyclohexyl)methyl)-7H-purine 

Relevant academic research and scientific papers

Electrocatalytic hydrogenation of benzoic acids in a proton-exchange membrane reactor

The highly efficient chemoselective electrocatalytic hydrogenation of benzoic acids (BAs) to cyclohexanecarboxylic acids (CCAs) was carried out in a proton-exchange membrane reactor under mild conditions without hydrogenation of the carboxyl group. Among the investigated catalysts, the PtRu alloy catalyst was found to be the most suitable for achieving high current efficiencies for production of CCAs. An electrochemical spillover mechanism on the PtRu alloy catalyst was also proposed.

Accessing Difluoromethylated and Trifluoromethylated cis-Cycloalkanes and Saturated Heterocycles: Preferential Hydrogen Addition to the Substitution Sites for Dearomatization

Reported here is a straightforward process in which a cyclic (alkyl)(amino)carbene/Rh catalyst system facilitates the preferential addition of hydrogen to the substitution sites of difluoromethylated and trifluoromethylated arenes and heteroarenes, leading to dearomative reduction. This strategy enables the diastereoselective synthesis of cis-difluoromethylated and cis-trifluoromethylated cycloalkanes and saturated heterocycles, and even allows formation of all-cis multi-trifluoromethylated cyclic products with a defined equatorial orientation of the di- and trifluoromethyl groups. Deuterium-labeling studies indicate that hydrogen preferentially attacks the substitution sites of planar arenes, resulting in dearomatization, possibly with heterogeneous Rh as the reactive species, followed by either reversible or irreversible hydrogen addition to the nonsubstitution sites.

Method for synthesizing cis-trifluoromethylcyclohexane derivatives and heterocyclic compounds by hydrogenation

The invention discloses a method for synthesizing cis-trifluoromethylcyclohexane derivatives and heterocyclic compounds by hydrogenation. The method is characterized in that trifluoromethylaromatic hydrocarbons or trifluoromethyl heterocyclic compounds ar

Epimerization of 2- or 4- substituted cyclohexanecarboxylic acids

The present invention relates to a new method for obtaining a purity of about 93% to 100% of the trans form of 2- or 4-substituted cyclohexanecarboxylic acid or reactive derivatives thereof from the cis form or a mixture of the cis and trans forms by a single step, particularly, to a method for obtaining a purity of substantially 100% of the trans form of 4-substituted cyclohexanecarboxylic acid.